Breakthrough IBD treatment heads into clinical trials
Posted: 17 February 2025 People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most difficult to treat conditions associated with the disease. IBD is the collective term…
Groundbreaking Research Sheds Light on Cerebellar Ataxias: Advancing Hope for Balance Disorder Treatment
Posted: 17 February 2025 At the Bionics Institute, we are committed to pushing the boundaries of medical research to address the most pressing and overlooked health challenges. One such challenge are the cerebellar ataxias, a devastating group of…
How advanced drug discovery tech is fast-tracking new treatments
Posted: 17 February 2025 On the same day that the National Drug Discovery Centre was officially launched at WEHI, the World Health Organization declared COVID-19 a pandemic. Within weeks, the NDDC had tested over 400,000 compounds to find starting points…
Illuccix Approved in the United Kingdom
Posted: 14 February 2025 Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of…
New research assists understanding of immune response to cancers, chronic disease
Posted: 13 February 2025 A discovery about the mechanisms that enable the immune system to sustain long-term protection could revolutionise treatment for chronic disease and cancer. Prolonged illnesses like cancer and chronic infections often leave the immune system…
New “all-tablet” treatment advance for common form of leukaemia
Posted: 10 February 2025 An international study published today in the New England Journal of Medicine provides hope for chronic lymphocytic leukaemia (CLL) patients with a new all-tablet treatment showing impressive results. The AMPLIFY clinical trial included over 800 never-before-treated…
Type C Meeting granted by FDA for Phelan-McDermid syndrome
Posted: 10 February 2025 Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted a Type C Meeting to discuss the primary efficacy endpoints in Neuren’s planned pivotal Phase 3 clinical trial…
High resolution retinal maps aid disease diagnoses
Posted: 6 February 2025 Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes, dementia and multiple sclerosis.…
Cell Bauhaus receives $3 million grant for digital twin research into cell behaviour
Posted: 6 February 2025 University of Melbourne affiliated startup Cell Bauhaus has received a $3 million grant from the Gates Foundation (formerly the Bill & Melinda Gates Foundation) to continue their work utilising digital twins to investigate how…
Australia’s TGA Approves Registration of CSL’s ANDEMBRY for the Prevention of Recurrent Hereditary Angioedema Attacks
Posted: 5 February 2025 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the registration of ANDEMBRY® (garadacimab) for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12…
Amplia completes recruitment of ACCENT Trial
Posted: 5 February 2025 Amplia has today announced that it has completed the planned enrolment of the ACCENT Phase 2a clinical trial. The two-stage ACCENT trial is investigating the use of the Company’s best-in-class FAK inhibitor narmafotinib in…
Investing In Medtech So Patients Can Breathe Easier
Posted: 5 February 2025 The Allan Labor Government is backing local medical technology startup Diag-Nose Medical to develop new treatments for chronic respiratory disorders, which has the potential to help millions of people worldwide. Minister for Economic Growth and…
